Coadministration of BRAFTOVI with a strong or moderate CYP3A inhibitor may increase encorafenibconcentrations; while coadministration of BRAFTOVI with a strong or moderate CYP3A inducer may

decrease encorafenib concentrations. Advise patients that they need to avoid certain medications whiletaking BRAFTOVI and to inform their healthcare provider of all concomitant medications, including

prescription medicines, over-the-counter drugs, vitamins, and herbal products. Advise patients to avoidgrapefruit or grapefruit juice while taking BRAFTOVI [see Drug Interactions (7.1)].

Storage

BRAFTOVI is moisture sensitive. Advise patients to store BRAFTOVI in the original bottle with desiccantand to keep the cap of the bottle tightly closed. Do not remove the desiccants from the bottle. 

Distributed by:

Array BioPharma Inc.

3200 Walnut Street

Boulder, CO 80301

© 2018 Array BioPharma Inc. All rights reserved.

BRAFTOVI™ is a trademark of Array BioPharma Inc.

Patented. See www.arraybiopharma.com/patents 

MEDICATION GUIDE

BRAFTOVI™ (braf-TOE-vee)

(encorafenib)

capsules

Important information: If your healthcare provider prescribes BRAFTOVI with binimetinib, please read the PatientInformation leaflet that comes with binimetinib.

What is the most important information I should know about BRAFTOVI?

BRAFTOVI may cause serious side effects, including:

Risk of new skin cancers. BRAFTOVI when used alone, or with binimetinib, may cause skin cancers calledcutaneous squamous cell carcinoma or basal cell carcinoma.

Talk to your healthcare provider about your risk for these cancers.

Check your skin and tell your healthcare provider right away about any skin changes, including a:

o new wart

o skin sore or reddish bump that bleeds or does not heal

o change in size or color of a mole

Your healthcare provider should check your skin before treatment with BRAFTOVI, every 2 months during treatment,and for up to 6 months after you stop treatment with BRAFTOVI to look for any new skin cancers.

Your healthcare provider should also check for cancers that may not occur on the skin. Tell your healthcare providerabout any new symptoms that develop during treatment with BRAFTOVI.

See "What are the possible side effects of BRAFTOVI?" for more information about side effects.

What is BRAFTOVI?

BRAFTOVI is a prescription medicine used in combination with a medicine called binimetinib to treat people with a type of

skin cancer called melanoma:

that has spread to other parts of the body or cannot be removed by surgery, and

that has a certain type of abnormal "BRAF" gene

BRAFTOVI should not be used to treat people with wild-type BRAF melanoma. Your healthcare provider will perform atest to make sure that BRAFTOVI is right for you.

It is not known if BRAFTOVI is safe and effective in children.

Before taking BRAFTOVI, tell your healthcare provider about all of your medical conditions, including if you:

 have had bleeding problems

 have eye problems

 have heart problems, including a condition called long QT syndrome

 have been told that you have low blood levels of potassium, calcium, or magnesium

 have liver or kidney problems